Stock quote - News

AstraZeneca
AZN: 6,793.00 -72.00 ( -1.05 %) delayed: 18:45PM


  • Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC
    Friday 13 Sep 2019 10:10

    Barclays Capital today reaffirms its overweight investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 8200p (from 8000p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Broker Forecast - Citigroup issues a broker note on AstraZeneca PLC
    Wednesday 11 Sep 2019 08:10

    Citigroup today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 10000p (from 7000p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC
    Monday 09 Sep 2019 09:50

    Deutsche Bank today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 7800p (from 7600p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • AstraZeneca says lung cancer treatment reduced death rates by 27%
    Monday 09 Sep 2019 08:56

    AstraZeneca said results from a clinical trial showed its lung cancer drug reduced the risk of death by more than a fifth in patients with previously-untreated extensive-stage small cell lung cancer. Imfinzi in combination with four cycles of standard-of-care (SoC) chemotherapy - etoposide...
    Read more

  • Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC
    Friday 06 Sep 2019 12:40

    Barclays Capital today reaffirms its overweight investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 8000p (from 7800p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • AstraZeneca lung cancer treatment gets regulatory nod in China
    Wednesday 04 Sep 2019 07:41

    AstraZeneca said its lung cancer drug received marketing approval in China as a 1st-line treatment based on results from a clinical trial. In the Flaura trial, 1st-line use of lung cancer drug Tagrisso provided a statistically-significant and clinically- meaningful improvement in...
    Read more

  • UK stocks hold on to gains at close
    Monday 02 Sep 2019 16:22

    UK stocks held on to earlier gains on Monday in what is set to be a pivotal week for British politics, as Boris Johnson faces potential attacks on his aggressive Brexit strategy and possibly his leadership from Tory rebels. At 1610, the benchmark FTSE 100 index was up 94.22 points, or 1.3%, at...
    Read more

  • UK stocks add to gains at midday
    Monday 02 Sep 2019 11:50

    UK stocks added to earlier gains on Monday in what is set to be a pivotal week for British politics, as Boris Johnson faces potential attacks on his aggressive Brexit strategy and possibly his leadership from Tory rebels. At 1140, the benchmark FTSE 100 index was up 95.63 points, or 1.3%, at...
    Read more

  • UK stocks open 0.6% higher as Brexit drama intensifies
    Monday 02 Sep 2019 09:03

    UK stocks opened higher on Monday in what is set to be a pivotal week for British politics, as Boris Johnson faces potential attacks on his aggressive Brexit strategy and possibly his leadership from Tory rebels. At 0854, the benchmark FTSE 100 index was up 41.66 points, or 0.6%, at 7.248.84....
    Read more

  • Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC
    Monday 02 Sep 2019 08:40

    Deutsche Bank today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 7600p (from 7200p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • AstraZeneca diabetes drug combined with standard care shows reduction in heart failure
    Monday 02 Sep 2019 07:28

    AstraZeneca said its type-2 diabetes drug on top of standard care showed a reduction in both the incidence of cardiovascular death and the worsening of heart failure in patients with and without type-2 diabetes. The trial of Farxiga (dapagliflozin) on top of standard of care showed a 30%...
    Read more

  • AstraZeneca announces 'positive' results from clinical trial
    Monday 02 Sep 2019 07:18

    AstraZeneca announced 'positive' results from its trial which showed that its cardiovascular drug, when combinbed with Aspirin, reduced the relative risk of heart attack or stroke by 10% compared with aspirin alone. The overall themis trial population included patients with coronary artery...
    Read more

  • FTSE firms thanks to sterling weakness boost
    Thursday 29 Aug 2019 16:46

    UK stocks climbed on Thursday amid weaker sterling, which fell in response to UK prime minister Boris Johnson's decision on Wednesday to prorogue parliament ahead of the Brexit deadline. Investors were also encouraged by China's fresh comments on potentially resolving the trade dispute with the...
    Read more

  • FTSE boosted by sterling weakness
    Thursday 29 Aug 2019 11:51

    UK stocks are climbing on Thursday amid weaker sterling, which fell in response to UK prime minister Boris Johnson's decision on Wednesday to prorogue parliament ahead of the Brexit deadline. Investors are also encouraged by China's fresh comments on potentially resolving the trade dispute with...
    Read more

  • UK stocks lifted by sterling weakness
    Thursday 29 Aug 2019 09:26

    UK stocks are climbing on Thursday amid weaker sterling, which fell in response to UK prime minister Boris Johnson's decision on Wednesday to prorogue parliament ahead of the Brexit deadline. At 08:58, the benchmark FTSE 100 was 0.67%, or 48.01 points, higher at 7,162.72. AstraZeneca added...
    Read more

  • AstraZeneca lupus drug meets primary goal in clinical trial
    Thursday 29 Aug 2019 07:14

    AstraZeneca said its lupus drug had met its primary goal in a clinical trial. The Phase III Tulip 2 trial for anifrolumab, a potential new medicine for the treatment of systemic lupus erythematosus (SLE), met its primary endpoint, achieving a 'statistically-significant and...
    Read more

  • AstraZeneca eosinophilic asthma treatment gets orphan drug designation
    Wednesday 28 Aug 2019 07:47

    AstraZeneca said its severe eosinophilic asthma treatment had received orphan drug designation from US Food and Drug Administration. The FDA grants orphan drug designation (ODD) status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases...
    Read more

  • AstraZeneca lung disease treatment meets primary goal
    Wednesday 28 Aug 2019 07:20

    AstraZeneca revealed positive results from its clinical trial for its triple-combination drug for lung disease sufferers. The trial met its primary endpoint showing that the company's triple-combination treatment reduced the risk of severe or moderate exacerbations in patients with chronic...
    Read more

  • UK market accelerates decline as US open fails to lift Fed rate rise doubts
    Thursday 22 Aug 2019 17:05

    UK share markets plunged farther and faster in late afternoon trade to close firmly in the red as a slow start to US trading failed to lift ongoing worries over US interest rate cuts following the release of minutes from the Federal Reserve's last policy meeting. Worries about the fragility of...
    Read more

  • Fed rate worries continue to drag on UK markets, buyout talk rallies NMC Health
    Thursday 22 Aug 2019 12:14

    UK share markets continue their decline at midday on Thursday as uncertainty over the outlook for US interest rate cuts following the release of minutes from the Federal Reserve's last policy meeting kept investors on edge. Worries about the fragility of the global economy were also evident in...
    Read more

  • UK stocks fall as market digests Fed minutes
    Thursday 22 Aug 2019 09:37

    UK stocks are falling on Thursday as the market digested the Wednesday's Federal Reserve July meeting minutes, which provided little clarity for future direction. At 08:58, the benchmark FTSE 100 was 0.40%, or 28.72 points, lower at 7,175.25. Antofagasta slipped 0.66% to 813.80p even as it said...
    Read more

  • AstraZeneca buys US Food and Drug Administration priority review voucher for $95m
    Thursday 22 Aug 2019 07:32

    AstraZeneca said it had agreed to buy a US Food and Drug Administration priority review voucher for $95m in cash from a subsidiary of Swedish Orphan Biovitrum. The voucher would give the company access to FDA priority review of a single new drug application or biologics license application,...
    Read more

  • AstraZeneca's anaemia treatment given regulatory nod in China
    Thursday 22 Aug 2019 07:31

    AstraZeneca said its drug to treat anaemia in non-dialysis-dependent patients suffering from chronic kidney disease had received marketing authorisation in China. 'With this approval for roxadustat in China, we are now able to provide this first-in-class medicine to all patients living with...
    Read more

  • FTSE 100 rises with markets in the mood to rally
    Wednesday 21 Aug 2019 16:42

    Wednesday finished as another positive session for the US and European indices, ahead of the Fed meeting minutes, with investors increasingly confident that central banks will step in to try and avert a recession, although sterling fell against both the dollar and the euro amid continuing...
    Read more

  • FTSE 100 firms ahead of US rates guidance
    Wednesday 21 Aug 2019 11:42

    UK stocks opened higher on Wednesday following a mixed lead from Asian exchanges, as investors braced for the release of US Fed minutes later in the day that could offer hints on the direction of interest rates. At 11.30, the benchmark FTSE 100 index was up 75 points at 7,200, or 1.05%, on a...
    Read more

  • UK stocks open 0.5% higher as investors await US rates guidance
    Wednesday 21 Aug 2019 08:47

    UK stocks opened higher on Wednesday following a mixed lead from Asian exchanges, as investors braced for the release of US Fed minutes later in the day that could offer hints on the direction of interest rates. At 0837, the benchmark FTSE 100 index was up 39.17 points, or 0.6%, at 7.164.17, on...
    Read more

  • AstraZeneca combination lung cancer treatment fails to meet primary goal
    Wednesday 21 Aug 2019 07:26

    AstraZeneca said a clinical trial of its lung cancer treatment failed to meet its primary goal of improving survival rates compared with chemotherapy. In the primary analysis population of patients whose blood tumour mutational burden was 20 or more mutations per megabase, the combination of...
    Read more

  • FTSE falls after Italian PM resigns
    Tuesday 20 Aug 2019 16:38

    UK stocks reversed their earlier gains to close well into the red on Tuesday after the resignation of Italian Prime Minister Giuseppe Conte opened a can of worms for markets across Europe. Also not helping the UK's leading index was the mid-afternoon gain in the pound, which made up ground from...
    Read more

  • FTSE stays higher with pound under pressure
    Tuesday 20 Aug 2019 12:02

    UK stocks remained higher on Tuesday as fears of a looming no-deal Brexit continued to heap pressure on the pound, helping exporters. Sterling clawed back a little ground on the dollar and euro, but was still significantly down with Brexit noise set to continue throughout the day as European...
    Read more

  • UK stocks open 0.5% higher; pound under pressure
    Tuesday 20 Aug 2019 08:59

    UK stocks opened higher on Tuesday as fears of a looming no-deal Brexit continued to heap pressure on the pound, helping exporters. At 0852, the benchmark FTSE 100 index was up 35.38 points, or 0.5%, at 7.225.03. Mining giant BHP fell 1.3% to 1,758.6p, despite declaring a record annual...
    Read more

  • AstraZeneca type-2 diabetes drug meets primary objective
    Tuesday 20 Aug 2019 07:21

    AstraZeneca said results from a clinical trial of its type-2 diabetes drug to treat patients with heart failure met its primary objective after showing a reduction of cardiovascular death or the worsening of heart failure when added to standard of care, compared to a placebo. The trial was...
    Read more

  • Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC
    Friday 16 Aug 2019 08:30

    Barclays Capital today reaffirms its overweight investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 7800p (from 7600p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Broker Forecast - UBS issues a broker note on AstraZeneca PLC
    Wednesday 14 Aug 2019 09:40

    UBS today reaffirms its sell investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 5700p (from 5400p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • AstraZeneca's leukaemia drug wins fast-track review from US Food and Drug Administration
    Wednesday 14 Aug 2019 07:21

    AstraZeneca said the US Food and Drug Administration had granted breakthrough therapy designation for its chronic lymphocytic leukaemia drug. The breakthrough therapy designation (BTD) status for Calquence, administered as a monotherapy treatment for adult patients with chronic lymphocytic...
    Read more

  • AstraZeneca and Merck ovarian cancer drug meets primary endpoint in clinical trial
    Wednesday 14 Aug 2019 07:14

    AstraZeneca and Merck said their ovarian cancer drug combined with bevacizumab had improved survival rates, meeting its primary goal during clinical trials. Women who took Lynparza plus bevacizumab lived longer without disease progression or death versus those taking bevacizumab alone, the...
    Read more

  • Cocktail of risks sours FTSE 100 performance
    Friday 09 Aug 2019 16:45

    A combination of economic and political risks in Italy, Asia the US and UK helped heap pressure on global equity markets on Friday. The FTSE 100 was not exempt, despite some support from weaker sterling, falling 0.4% to 7,253.85. The subdued sentiment saw the US S&P 500 slip 1.1% to 2,904.27...
    Read more

  • FTSE gathers some ground after GDP-inspired fall for the pound
    Friday 09 Aug 2019 12:08

    A weaker than expected UK GDP print put pressure on sterling which in turn lifted the export-heavy FTSE 100. Although still just about in the red, the index was off its lows at 7,280.76. Fading optimism over trade relations between the US and China is expected to see US markets give back some...
    Read more

  • AstraZeneca reveals positive results from trial of lung cancer drug
    Friday 09 Aug 2019 07:46

    AstraZeneca announced positive results from its clinical trial for its metastatic non-small cell lung cancer drug, which had 'significantly improved survival rates. Tagrisso showed a statistically-significant and clinically-meaningful improvement in overall survival, a secondary endpoint in...
    Read more

  • AstraZeneca and Merck prostate cancer drug meets primary endpoint in clinical trial
    Wednesday 07 Aug 2019 07:12

    AstraZeneca and Merck said their castration-resistant prostate cancer drug had met its primary endpoint in clinical trials. The trial of Lynparza had shown showed a statistically-significant and clinically-meaningful improvement in the primary endpoint of radiographic progression-free survival...
    Read more

  • Broker Forecast - Goldman Sachs issues a broker note on AstraZeneca PLC
    Tuesday 06 Aug 2019 09:10

    Goldman Sachs today reaffirms its sell investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 5500p (from 5000p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • AstraZeneca's type-2 diabetes drug label updated in EU with positive outcomes, data from trial
    Monday 05 Aug 2019 07:33

    AstraZeneca said the European Commission had approved an update to the marketing authorisation for the company's type-2 diabetes drug to include positive results from a phase 3 drug trial. In the Phase III DECLARE-TIMI 58 trial, the company's type 2 diabetes drug Forxiga achieved a...
    Read more

  • Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC
    Monday 29 Jul 2019 08:30

    Deutsche Bank today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 7200p (from 6900p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC
    Friday 26 Jul 2019 09:50

    Barclays Capital today reaffirms its overweight investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 7600p (from 7500p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • FTSE down as ECB warns on outlook
    Thursday 25 Jul 2019 16:43

    The FTSE 100 again closed below the 7,500 mark on Thursday after the European Central Bank hinted at an interest rate cut in September. It kept interest rates unchanged, but in a news conference, ECB boss Mario Draghi said the outlook is getting 'worse and worse' for the Eurozone economy,...
    Read more

  • FTSE dips ahead of possible ECB rate cut
    Thursday 25 Jul 2019 11:58

    UK stocks have dipped slightly from early morning trading on Thursday as investors cautiously wait to see whether the European Central Bank will cut interest rates this afternoon. At 11:51, the benchmark FTSE 100 was up 0.11%, or 8.79 points, at 7,510.25. LARGE AND MID CAP RISERS AND FALLERS...
    Read more

  • UK stocks rise ahead of ECB interest rate decision
    Thursday 25 Jul 2019 09:38

    UK stocks are edging higher on Thursday morning as investors await the outcome of the European Central Bank's latest interest rate decision later in the session. At 08:58, the benchmark FTSE 100 was up 0.26%, or 19.39 points, at 7,520.85. Aveva was last seen up 1.31% at 4,010p after it said...
    Read more

  • AstraZeneca lifts product sales guidance amid stronger H1
    Thursday 25 Jul 2019 07:31

    AstraZeneca upgraded its product sales guidance as an acceleration in second-quarter sales bolstered its first-half performance. Product sales in 2019 were now expected to increase by a low double-digit percentage; the prior guidance was for a high single-digit percentage increase. The...
    Read more

  • FTSE regains its poise by lunchtime
    Monday 15 Jul 2019 12:07

    The FTSE 100 was up by midday, advancing 0.2% to 7,520.77 after slipping into the red earlier. Investors apparently focused on the positive elements of China's latest growth figures, announced overnight. Retailers were in the doghouse after weak industry figures and insurance stocks also took...
    Read more

  • UK stocks open slightly higher after mixed Chinese economic data
    Monday 15 Jul 2019 08:57

    UK stocks opened slightly higher on Monday after the release of a mixed set of Chinese data that showed economic growth slowing but better-than-expected industrial output and retail sales. At 0850, the benchmark FTSE 100 index was up 3.29 points at 7.509.26. Sports Direct International sank 12%...
    Read more

  • AstraZeneca's Type-1 diabetes treatment fails to get FDA approval
    Monday 15 Jul 2019 07:42

    AstraZeneca said the U.S. Food and Drug Administration had decided against approving the company's application for its diabetes drug. The drugmaker said it would work closely with the FDA to discuss the next steps after receiving a complete response letter from the US health regulator declining...
    Read more

Page 1 |

Risk warning: Remember the price of shares can go down as well as up, and you are not guaranteed to get back the amount that you originally invested.
Click here to read the full warning.